BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 11294012)

  • 1. Isolation, sequence and genotyping of the drug metabolizer CYP2D6 gene in the Colombian population.
    Isaza CA; Henao J; López AM; Cacabelos R
    Methods Find Exp Clin Pharmacol; 2000 Nov; 22(9):695-705. PubMed ID: 11294012
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High prevalence of
    P Sarmiento A; Dorado P; Borbón A; de Andrés F; LLerena A;
    Pharmacogenomics; 2020 Nov; 21(17):1227-1236. PubMed ID: 33124522
    [No Abstract]   [Full Text] [Related]  

  • 3. Allele and genotype frequencies of CYP2C9, CYP2C19 and CYP2D6 in an Italian population.
    Scordo MG; Caputi AP; D'Arrigo C; Fava G; Spina E
    Pharmacol Res; 2004 Aug; 50(2):195-200. PubMed ID: 15177309
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of the predictive power of genotypes for the in-vivo catalytic function of CYP2D6 in a German population.
    Griese EU; Zanger UM; Brudermanns U; Gaedigk A; Mikus G; Mörike K; Stüven T; Eichelbaum M
    Pharmacogenetics; 1998 Feb; 8(1):15-26. PubMed ID: 9511177
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polymorphisms in CYP2D6 duplication-negative individuals with the ultrarapid metabolizer phenotype: a role for the CYP2D6*35 allele in ultrarapid metabolism?
    Løvlie R; Daly AK; Matre GE; Molven A; Steen VM
    Pharmacogenetics; 2001 Feb; 11(1):45-55. PubMed ID: 11207030
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I.
    Zhou SF
    Clin Pharmacokinet; 2009; 48(11):689-723. PubMed ID: 19817501
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry.
    Zanger UM; Raimundo S; Eichelbaum M
    Naunyn Schmiedebergs Arch Pharmacol; 2004 Jan; 369(1):23-37. PubMed ID: 14618296
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interethnic variability of CYP2D6 alleles and of predicted and measured metabolic phenotypes across world populations.
    LLerena A; Naranjo ME; Rodrigues-Soares F; Penas-LLedó EM; Fariñas H; Tarazona-Santos E
    Expert Opin Drug Metab Toxicol; 2014 Nov; 10(11):1569-83. PubMed ID: 25316321
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Frequency of single nucleotide polymorphisms of CYP2D6 in the Czech population.
    Buzková H; Pechandová K; Slanar O; Perlík F
    Cell Biochem Funct; 2008; 26(1):76-81. PubMed ID: 17311358
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences.
    Sachse C; Brockmöller J; Bauer S; Roots I
    Am J Hum Genet; 1997 Feb; 60(2):284-95. PubMed ID: 9012401
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detection of CYP2D6*3 and 2D6*4 allelic variants by PCR-restriction fragment length polymorphism.
    Topić E; Stefanović M; Nikolić V; Zoricić I; Ivanisević AM; Zuntar I
    Clin Chem Lab Med; 1998 Aug; 36(8):655-8. PubMed ID: 9806480
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CYP2D6 genotype and phenotype determination in a Mexican Mestizo population.
    López M; Guerrero J; Jung-Cook H; Alonso ME
    Eur J Clin Pharmacol; 2005 Nov; 61(10):749-54. PubMed ID: 16249913
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Unique CYP2D6 activity distribution and genotype-phenotype discordance in black Americans.
    Gaedigk A; Bradford LD; Marcucci KA; Leeder JS
    Clin Pharmacol Ther; 2002 Jul; 72(1):76-89. PubMed ID: 12152006
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence of the CYP2D6*10 (C100T), *4 (G1846A), and *14 (G1758A) alleles among Iranians of different ethnicities.
    Bagheri A; Kamalidehghan B; Haghshenas M; Azadfar P; Akbari L; Sangtarash MH; Vejdandoust F; Ahmadipour F; Meng GY; Houshmand M
    Drug Des Devel Ther; 2015; 9():2627-34. PubMed ID: 25999696
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Polymorphisms and phenotypic analysis of cytochrome P450 2D6 in the Tibetan population.
    Jin TB; Ma LF; Zhang JY; Yuan DY; Sun Q; Zong TY; Geng TT; Cui YL; Kang LL; Chen C
    Gene; 2013 Sep; 527(1):360-5. PubMed ID: 23644254
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CYP2D6 polymorphism in a Mexican American population.
    Mendoza R; Wan YJ; Poland RE; Smith M; Zheng Y; Berman N; Lin KM
    Clin Pharmacol Ther; 2001 Dec; 70(6):552-60. PubMed ID: 11753272
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Results and challenges of Cytochrome P450 2D6 (CYP2D6) testing in an ethnically diverse South Florida population.
    Salyakina D; Roy S; Wang W; Oliva M; Akhouri R; Sotto I; Mulas N; Solano R; Fernández JR; Sanchez S; Shamshad U; Perlyn C; McCafferty-Fernandez J
    Mol Genet Genomic Med; 2019 Sep; 7(9):e922. PubMed ID: 31389673
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic polymorphism in cytochrome P450 2D6 (CYP2D6): Population distribution of CYP2D6 activity.
    Neafsey P; Ginsberg G; Hattis D; Sonawane B
    J Toxicol Environ Health B Crit Rev; 2009; 12(5-6):334-61. PubMed ID: 20183526
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CYP2D6 genotyping in patients on psychoactive drug therapy.
    Topić E; Stefanović M; Ivanisević AM; Blazinić F; Culav J; Skocilić Z
    Clin Chem Lab Med; 2000 Sep; 38(9):921-7. PubMed ID: 11097351
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of a PCR-based strategy for CYP2D6 genotyping including gene multiplication of worldwide potential use.
    Dorado P; Cáceres MC; Pozo-Guisado E; Wong ML; Licinio J; Llerena A
    Biotechniques; 2005 Oct; 39(4):571-4. PubMed ID: 16235570
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.